` ORMP (Oramed Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ORMP
vs
S&P 500

Over the past 12 months, ORMP has significantly outperformed S&P 500, delivering a return of +65% compared to S&P 500's +10% growth.

Stocks Performance
ORMP vs S&P 500

Loading...
ORMP
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ORMP vs S&P 500

Performance Gap Between ORMP and GSPC

Create a free account · No card needed

Performance By Year
ORMP vs S&P 500

Loading...
ORMP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Oramed Pharmaceuticals Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Oramed Pharmaceuticals Inc
Glance View

Market Cap
166.4m USD
Industry
Pharmaceuticals

Oramed Pharmaceuticals is a biopharmaceutical company that focuses on taking medicines that are usually injected and turning them into pills. Its best-known work is around oral insulin for people with diabetes, along with other oral drug delivery programs built on the same idea. The company is still mainly a development-stage business, so its value comes from its science and the medicines it is trying to bring to market rather than from a broad catalog of sold products. Its main customers would be patients and doctors if its therapies are approved, but today most of its business comes from research and development work, licensing arrangements, and partnerships with other drug companies. In simple terms, Oramed makes money by advancing its drug candidates, granting rights to its technology, and working with partners who may fund or commercialize parts of the platform. That makes it different from a traditional drug maker that mostly sells approved medicines directly. The company’s role in the industry is to solve a hard problem: getting fragile medicines like insulin through the digestive system so they can be absorbed by the body. If that approach works, it could make some treatments easier to use and more convenient for patients than injections. Oramed’s business depends on proving that its oral delivery technology can work reliably, which is why development, testing, and partnerships are central to how it grows.

ORMP Intrinsic Value

Create a free account · No card needed

Back to Top